Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’

The success of Novo’s weight-loss treatments has transformed the drugmaker into Europe’s most valuable company and made it a key driver of domestic economic growth. Read More